Mr. Nakae: The focus of the conference is emerging growth life sciences and therefore the smaller cap names within that space. Most of the companies that will be presenting will have market caps anywhere in the range of $50 million to around $1 billion. We will also have a few private companies that are developing interesting products.
TWST: In general terms, what has gone on from a market perspective in
that group so far this year?
Mr. Nakae: Within the medical device sector, the small cap group and the
micro-cap group have had different performances. The small cap group,
which I would classify as stocks with market caps between $200 million
and $1 billion, has done well. The micro-cap group, which I would
classify as stocks with a market cap under $200 million, has performed
poorly this year.
Tickers included in this excerpt: AMMD, ANSI, BSX, CLN, CYBX, DBMI, ELOS, EPMD, GB, GDT, JNJ, LSCP, M, MDT, RITA, RTIX, SHMR, STJ, SYK, THOR, ULGX
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.